<?xml version="1.0" encoding="UTF-8"?>
<rootTag>
<Award>
<AwardTitle>I-Corps: Acellular 3D Scaffold for Treating Volumetric Muscle Loss</AwardTitle>
<AGENCY>NSF</AGENCY>
<AwardEffectiveDate>08/15/2020</AwardEffectiveDate>
<AwardExpirationDate>01/31/2021</AwardExpirationDate>
<AwardTotalIntnAmount>50000.00</AwardTotalIntnAmount>
<AwardAmount>50000</AwardAmount>
<AwardInstrument>
<Value>Standard Grant</Value>
</AwardInstrument>
<Organization>
<Code>07070000</Code>
<Directorate>
<Abbreviation>ENG</Abbreviation>
<LongName>Directorate For Engineering</LongName>
</Directorate>
<Division>
<Abbreviation>IIP</Abbreviation>
<LongName>Div Of Industrial Innovation &amp; Partnersh</LongName>
</Division>
</Organization>
<ProgramOfficer>
<SignBlockName>Ruth Shuman</SignBlockName>
<PO_EMAI>rshuman@nsf.gov</PO_EMAI>
<PO_PHON>7032922160</PO_PHON>
</ProgramOfficer>
<AbstractNarration>The broader impact/commercial potential of this I-Corps project is the development of an implantable medical device to facilitate the regeneration of skeletal muscle to reduce unnecessary suffering and cost from long-term disability following traumatic muscle injuries. This device may change the standard of care for large muscle injuries and save limbs that otherwise would be amputated. This project will explore the translation of technologies that restore muscle and limit disability in 65,000 annual gunshot victims; 110,000 annual open fracture victims; and 10,000 annual active duty service personnel suffering with traumatic muscle injuries in the US. In addition, the technology may have applications in veterinary medicine to help veterinarian surgeons improve the quality of life for traumatic injuries in pets and livestock. There are more than 158,000 muscle injuries in dogs alone within the US and Canada every year. A successful entrance into the veterinarian market may provide additional safety and efficacy data for a future FDA clearance for human use.&lt;br/&gt;&lt;br/&gt;This I-Corps project is based on the development of a 3D biomaterial that will enable surgeons to treat large muscle injuries and improve functional outcomes.  The proposed device is an extracellular replacement therapy to facilitate functional and aesthetic healing of skeletal muscle injuries. The proposed technology is based on proteins normally found in developing muscles, and a 3D porous structure that allows cells to attach while filling the entirety of the injury. The mechanical properties physically prevent the wound from collapsing on itself, and the interconnected porous structure allows for cellular infiltration of remaining skeletal muscle cells and immune cells. The product is designed to be shelf stable and fit within a surgeonâ€™s pre-existing surgical routine.  A single device may be cut to fit the specific defect and return the muscles' natural contour. Previous studies have shown an improvement in muscle function by 52%.&lt;br/&gt;&lt;br/&gt;This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.</AbstractNarration>
<MinAmdLetterDate>08/24/2020</MinAmdLetterDate>
<MaxAmdLetterDate>10/14/2020</MaxAmdLetterDate>
<ARRAAmount/>
<TRAN_TYPE>Grant</TRAN_TYPE>
<CFDA_NUM>47.041</CFDA_NUM>
<NSF_PAR_USE_FLAG>1</NSF_PAR_USE_FLAG>
<FUND_AGCY_CODE>4900</FUND_AGCY_CODE>
<AWDG_AGCY_CODE>4900</AWDG_AGCY_CODE>
<AwardID>2041485</AwardID>
<Investigator>
<FirstName>Koyal</FirstName>
<LastName>Garg</LastName>
<PI_MID_INIT/>
<PI_SUFX_NAME/>
<PI_FULL_NAME>Koyal Garg</PI_FULL_NAME>
<EmailAddress>koyal.garg@slu.edu</EmailAddress>
<PI_PHON>8044264781</PI_PHON>
<NSF_ID>000831815</NSF_ID>
<StartDate>08/24/2020</StartDate>
<EndDate/>
<RoleCode>Principal Investigator</RoleCode>
</Investigator>
<Institution>
<Name>Saint Louis University</Name>
<CityName>St Louis</CityName>
<ZipCode>631032006</ZipCode>
<PhoneNumber>3149773925</PhoneNumber>
<StreetAddress>221 N. Grand Blvd.</StreetAddress>
<StreetAddress2/>
<CountryName>United States</CountryName>
<StateName>Missouri</StateName>
<StateCode>MO</StateCode>
<CONGRESSDISTRICT>01</CONGRESSDISTRICT>
<CONGRESS_DISTRICT_ORG>MO01</CONGRESS_DISTRICT_ORG>
<ORG_DUNS_NUM>050220722</ORG_DUNS_NUM>
<ORG_LGL_BUS_NAME>SAINT LOUIS UNIVERSITY</ORG_LGL_BUS_NAME>
<ORG_PRNT_DUNS_NUM>050220722</ORG_PRNT_DUNS_NUM>
</Institution>
<Performance_Institution>
<Name><![CDATA[GenAssist]]></Name>
<CityName>Saint Louis</CityName>
<StateCode>MO</StateCode>
<ZipCode>631101110</ZipCode>
<StreetAddress><![CDATA[4340 Duncan Ave]]></StreetAddress>
<CountryCode>US</CountryCode>
<CountryName>United States</CountryName>
<StateName>Missouri</StateName>
<CountryFlag>1</CountryFlag>
<CONGRESSDISTRICT>01</CONGRESSDISTRICT>
<CONGRESS_DISTRICT_PERF>MO01</CONGRESS_DISTRICT_PERF>
</Performance_Institution>
<ProgramElement>
<Code>8023</Code>
<Text>I-Corps</Text>
</ProgramElement>
<Appropriation>
<Code>0120</Code>
<Name>NSF RESEARCH &amp; RELATED ACTIVIT</Name>
<APP_SYMB_ID>040100</APP_SYMB_ID>
</Appropriation>
<FUND_OBLG>2020~50000</FUND_OBLG>
<POR>
<DRECONTENT><![CDATA[<div class="porColContainerWBG"> <div class="porContentCol"><p>The goal of this grant was to determine whether or not there was a substantial veterinary market for Volumetric muscle loss (VML). In order to do this, we interviewed pet owners and pet veterinarians to find out if enough pets suffered from VML to justify the costs of commercialization. We found that there weren't many cases where improving muscle regeneration would significantly benefit pet owners, who were the buyers in this scenario.&nbsp;</p> <p>Next, we interviewed K-9 trainers to find out if police dogs sustained musculoskeltal injuries that lead to early retirement. We proposed that we could save training time and costs by preventing early retirement to k-9 units from muscle loss. We found that ealry k-9 retirement does not happen often, and unfortunately, the serious injuries that do occur result in death.&nbsp;</p> <p>Next, we targeted the equine market, specifically racing horses. We interviewed stable runners, racehorse trainers, and horse veterinarians. They told us about their concerns about fibrotic myopathy, and how it can lead to early retirement of horses that cost millions of dollars to train. This seemed promising and we thought it was something we could treat. However, after further market research and interviews, we found that there were only a couple cases of it per year.</p> <p>After this, we pivoted to the human orthopedic surgery market. As we expected, there was more excitement from orthopedic surgeons who frequently have patients who suffer from frank loss of muscle. They told us if we could reduce overall treatment costs and improve muscle strength outcomes, without posing major infection risk, Value analysis commmittees at hospitals would be willing to try out our product.&nbsp;</p><br> <p>            Last Modified: 06/07/2021<br>      Modified by: Koyal&nbsp;Garg</p> </div> <div class="porSideCol"></div> </div>]]></DRECONTENT>
<POR_COPY_TXT><![CDATA[ The goal of this grant was to determine whether or not there was a substantial veterinary market for Volumetric muscle loss (VML). In order to do this, we interviewed pet owners and pet veterinarians to find out if enough pets suffered from VML to justify the costs of commercialization. We found that there weren't many cases where improving muscle regeneration would significantly benefit pet owners, who were the buyers in this scenario.   Next, we interviewed K-9 trainers to find out if police dogs sustained musculoskeltal injuries that lead to early retirement. We proposed that we could save training time and costs by preventing early retirement to k-9 units from muscle loss. We found that ealry k-9 retirement does not happen often, and unfortunately, the serious injuries that do occur result in death.   Next, we targeted the equine market, specifically racing horses. We interviewed stable runners, racehorse trainers, and horse veterinarians. They told us about their concerns about fibrotic myopathy, and how it can lead to early retirement of horses that cost millions of dollars to train. This seemed promising and we thought it was something we could treat. However, after further market research and interviews, we found that there were only a couple cases of it per year.  After this, we pivoted to the human orthopedic surgery market. As we expected, there was more excitement from orthopedic surgeons who frequently have patients who suffer from frank loss of muscle. They told us if we could reduce overall treatment costs and improve muscle strength outcomes, without posing major infection risk, Value analysis commmittees at hospitals would be willing to try out our product.        Last Modified: 06/07/2021       Submitted by: Koyal Garg]]></POR_COPY_TXT>
</POR>
</Award>
</rootTag>
